Market Research Report
Global Influenza Therapeutics Market - 2019-2026
|Published by||DataM Intelligence||Product code||916174|
Delivery time: 1-2 business days
|Global Influenza Therapeutics Market - 2019-2026|
|Published: January 1, 2020||Content info:||
Influenza Therapeutics Market Overview
Influenza commonly called as flu, is a contagious viral infection that attacks the respiratory system of a human being. Symptoms of influenza involve muscle aches and soreness, headache, and fever. There are three types of flu viruses: A, B, and C. Type A and B cause the annual influenza epidemics that have up to 20% of the population sniffling, aching, coughing, and running high fevers. Worldwide, these annual epidemics are estimated to result in about three to five million cases of severe illness, and about 290,000 to 650,000 respiratory deaths. Type C also causes flu; however, type C flu symptoms are much less severe.
The global influenza therapeutics market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, at a CAGR of 7.2% during the forecast period (2019-2026).
Influenza Therapeutics Market Dynamics
The influenza therapeutics market growth is driven by several factors, such as a rise in the prevalence of influenza, growth in geriatric population and increase in government funding.
Influenza viruses are highly unstable and capable of causing pandemics. A novel influenza virus can result through the exchange of genetic material among viruses from a different animal, avian or human hosts. Influenza A (H1N1) continues to pose a significant challenge to public health, causing many deaths each year and will continue to have a similar trend, in near future. While most cases have resulted in mild and uncomplicated illnesses, many deaths have occurred, and the case fatality rate is higher than that in many other countries. The presence of underlying chronic conditions, for e.g., cardiovascular disease, neuromuscular disease, immunosuppressive medications, and immunodeficiency, increases the risk of severe influenza, so the prevalence of these conditions can influence the proportion of influenza illnesses that are severe or fatal. According to the World Health Organization (WHO), globally, the number of deaths due to cardiovascular diseases has increased by 41% between 1990 and 2013, of which the number of influenza effected patients were low to moderate. Conditions such as malnutrition, pregnancy, immediate post-partum period, and obesity especially morbid obesity may also increase the risk of severe or fatal influenza. Other factors include climate, which plays an important role in the spread of influenza viruses, with well-documented seasonal peaks of influenza illness and death in populations in temperate climates. Climatic disturbances are widespread in many parts of the world due to global warming. Other factors likely to influence risk of a severe or fatal outcome are the availability of medical care, like oxygen and ventilatory support, the prompt use of anti-viral drugs, and the use of antimicrobials to treat concurrent or resultant bacterial infections.
The government of various countries are funding for the proper vaccination of influenza worldwide, and this leads to more people opting for treatment and hence supporting the growth of the market. For instance, in Taiwan the Ministry of Health and Welfare announced in 2019 that in order to provide more comprehensive protection against influenza for the public, the Executive Yuan has approved that the government-funded influenza vaccinations would be changed from trivalent to quadrivalent vaccines (including two influenza A viruses and two influenza B viruses) starting next flu season. Similarly, in Australia children aged six months to less than five years of age are eligible to receive the influenza vaccine Fluarix Tetra® for free under the State Funded Childhood Influenza Program. Moreover, as part of the 2019 Annual Influenza Program, free flu vaccination is available for people who are at greater risk of disease and developing complications if they get the flu. These programs help raise awareness about the disease as well as increase the patients that receive treatment, hence boosting the global influenza therapeutics market.
Influenza Therapeutics Market Segment Analysis
By therapy type, the global influenza therapeutics market is segmented into vaccines and antiviral drugs. Vaccines are expected to be the primary market shareholder over the period of forecast (2019-2026) as the flu vaccine is the most effective way to prevent illness caused by seasonal influenza viruses. The Center for Disease Control and Prevention (CDC) estimates that the flu vaccine reduces a person's risk of developing flu-related illness severe enough to require a doctor's visit by 61%. Influenza vaccines are of two types trivalent and quadrivalent. Flu vaccines also lessen the spread of the virus as it protects against the outbreak of the disease to a great extent. Influenza can be deadly, and there are pandemics to prove that these can be entirely avoided by taking influenza vaccines. Influenza vaccines are also covered by many health plans such as the Affordable Care Act. Under the Affordable Care Act, non-grandfathered, private health plans will cover a range of recommended preventive services with no cost-sharing (such as copays and deductibles) by the beneficiary, including vaccinations recommended by the CDC's Advisory Committee on Immunization Practices.
By end-user the global market is segmented into hospitals, retail pharmacies, and online pharmacies.
Influenza Therapeutics Market Geographical Analysis
North America is dominating the influenza therapeutics market in 2018 and estimated to hold the largest market size over the forecast period (2019-2026), owing to an increase in incidences of influenza, a highly aware population, advanced healthcare infrastructure and, favorable government initiatives and reimbursement policies. According to CDC, in 2019 a different strain of the flu virus, a "variant" virus, accounts for 46.9% of the influenza cases. CDC estimates that influenza has resulted in between 9.3 million to 49 million illnesses, between 140,000 to 960,000 hospitalizations, and between 12,000 to 79,000 deaths in US annually since 2010. In Canada, Public Health Agency of Canada, the Canadian Nurses Coalition on Immunization, and the Canadian Immunization Committee have worked together since July 2004 to develop and update the database containing the latest provincial/territorial immunization program information and providing immunization during the flu season. Ontario Ministry of Health has a Universal Influenza Immunization Program during the influenza season. The program offers influenza vaccine free of charge each year to all individuals six months of age and older who live, work or go to school in Ontario.
Influenza Therapeutics Market Competitive Landscape
Some of the major key players in the market are Sanofi SA, AstraZeneca Plc, Biocryst Pharmaceuticals Inc., CSL Limited, Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Mitsubishi Tanabe Pharma Corporation, Ology Bioservices, Shionogi & Co. Ltd. and, Roche Holding AG.
Sanofi dominates the influenza therapeutics market, owning to vaccines portfolio expansion, mergers, collaborations, and acquisitions with the companies who are specifically into vaccines manufacturing. The key players are adopting various growth strategies such as mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, which are contributing to the growth of the influenza therapeutics market globally.
In October 2019, Roche announced that the US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for XofluzaTM (baloxavir marboxil) for the treatment of acute, uncomplicated influenza.
In October 2019, Mitsubishi Tanabe Pharma Corporation announced that its affiliated company Medicago Inc. has released that Health Canada had accepted New Drug Submission for a plant-based quadrivalent virus-like particle influenza recombinant vaccine for scientific review.
In May 2019, Daiichi Sankyo Company, Limited announced that the company has been unable to fulfill its obligation to build a scheme to supply vaccines for 40 million people in the time allotted under the Japanese Ministry of Health, Labour and Welfare's cell culture vaccine production facility capacity building project, which is a part of the Ministry's second initiative for H5NI vaccine development and production capacity-building grant.
In March 2019, GlaxoSmithKline announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for intravenous zanamivir for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and pediatric patients.
The Global Influenza Therapeutics Market report would provide an access to an approx., 53 market data table, 41 figures, and 190 pages.
Global Influenza Therapeutics Market Methodology and Scope
List not exhaustive